Effect of HIV-infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract by Cottrell, Mackenzie L et al.
Effect of HIV Infection and Menopause Status on Raltegravir 
Pharmacokinetics in the Blood and Genital Tract
Mackenzie L. Cottrell, PharmD, MS1, Kristine B. Patterson, MD2, Heather M.A. Prince, PA-
C1, Amanda Jones, PharmD3, Nicole White, BS1, Ruili Wang, MD1, and Angela D.M. 
Kashuba, PharmD, DABCP1,2
1 University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Chapel Hill, North 
Carolina, USA
2University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina, USA
3Salix Pharmaceuticals, Raleigh, North Carolina, USA
Abstract
Background—This study describes first dose and steady state pharmacokinetics of raltegravir 
(RAL) in cervicovaginal fluid (CVF) and blood plasma (BP).
Methods—Three cohorts of women were enrolled sequentially in a single-site, open-label 
pharmacokinetic study of oral raltegravir 400 mg twice daily: HIV-negative premenopausal, HIV-
infected premenopausal, and HIV-infected postmenopausal women. BP and CVF were collected 
over 12 hours after a single observed dose and at steady state. RAL concentrations were measured 
by HPLC-MS methods. Data are expressed as median (interquartile range [IQR]). The ANOVA 
rank sum test was used to evaluate between-group differences in steady state raltegravir exposure 
(AUC0-12h).
Results—First dose PK was obtained in HIV-negative premenopausal women and HIV-infected 
postmenopausal women only. The median(IQR) BP AUC0-12h was 3099(985-5959) and 
4239(2781-13695)ng*hr/mL and the median(IQR) CVF AUC0-12h was 1720(305-5288) and 
13797(11066-19563)ng*hr/mL for HIV-negative premenopausal and HIV-infected 
postmenopausal women, respectively. All cohorts contributed to steady state pharmacokinetic 
profiles. Median(IQR) BP AUC0-12h did not differ between the groups: 8436(3080-10111), 
5761(1801-10095) and 6180(5295-8282)ng*hr/mL in HIV-negative premenopausal, HIV-infected 
premenopausal, and HIV-infected postmenopausal women, respectively. There was a trend for 
lower CVF AUC0-12h among HIV-negative women 3164(1156-9540) compared to 
11465(9725-17138) and 9568(4271-24306)ng*hr/mL HIV-infected premenopausal, and HIV-
infected postmenopausal women, respectively, but this was not statistically significant (p=0.08). 
HIV-negative premenopausal women had a median(IQR) CVF:BP AUC0-12h ratio of 0.46(0.2-1.1), 
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whereas HIV-infected premenopausal and postmenopausal women had median(IQR) CVF:BP 
AUC0-12h ratio of 3.9(1.2-6.7) and 1.4(0.7-4.3), respectively.
Conclusions—This is the first study to investigate RAL exposure in BP and CVF in 
premenopausal HIV-negative and pre and postmenopausal HIV-infected women. These data 
indicate HIV and menopausal status may influence antiretroviral distribution into the female 
genital tract.
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Introduction
Worldwide, the incidence of HIV remains relatively stable despite improved global 
availability of potent antiretroviral therapy [1]. The primary route of transmission for new 
HIV infections is sexual contact [2]. Consistent suppression of plasma viral load with 
antiretroviral therapy reduces transmission [3]. However, sexual transmission of HIV 
infection on antiretroviral therapy can still occur[4] presumably due to persistent HIV 
replication in the genital tract of source patients [5,6]. Additionally, with emerging evidence 
suggesting that cells in tissues may continue to produce low levels of HIV despite 
suppression with antiretroviral therapy[7], eradicating virus from susceptible anatomical 
sites like the female genital tract may be an important goal for HIV cure.
The unique mechanism of action of integrase strand inhibitors (INSTI) may make this class 
particularly well suited to suppress HIV replication in the genital tract. Raltegravir 
(Isentress®, Merck Sharp & Dohme Corp, Whitehouse, NJ, USA), the first of three FDA 
approved INSTIs, is potent and well-tolerated [8]. We have previously demonstrated that 
raltegravir rapidly distributes to gut-associated lymphoid and rectal tissue with high 
exposure [9]. Characterizing the extent to which raltegravir penetrates into the female genital 
tract will assist in determining raltegravir’s potential utility for primary and secondary HIV 
prevention and HIV eradication. This study aimed to characterize the first dose and steady 
state pharmacokinetics of raltegravir in cervicovaginal fluids (CVF) and blood plasma (BP) 
in three populations of female volunteers who would be candidates for primary and 
secondary HIV prevention and eradication: HIV-negative premenopausal women, HIV-
infected premenopausal women, and HIV-infected postmenopausal women.
Methods
Study Design and Subject Selection
This was an open-label, single-center pharmacokinetic study of oral raltegravir 400mg dosed 
twice daily in three unique female cohorts: HIV-negative premenopausal women, HIV-
infected premenopausal women, and HIV-infected postmenopausal women. Each of the 
three study protocols were approved by the UNC Biomedical Institutional Review Board, 
and registered on clinicaltrials.gov under the identifiers NCT00961272, NCT00746499, and 
NCT00666055, respectively. All study activities were carried out in accordance with the 
ethical standards of the International Conference on Harmonization E6 Good Clinical 
Cottrell et al. Page 2













Practice Guidance. Informed consent was obtained from all participants prior to any study 
activities. HIV-negative premenopausal women were enrolled between August and October 
2008, HIV-infected premenopausal women were enrolled between July 2009 and January 
2010, and HIV-infected postmenopausal women were enrolled between May 2008 and 
December 2010. At the time of study initiation, raltegravir was a newly approved “first in 
class” antiretroviral, which limited the number of women of childbearing potential receiving 
raltegravir for HIV treatment as well as providers willing to switch virologically-suppressed 
women to raltegravir. Therefore, to facilitate enrollment HIV-infected premenopausal 
women already on raltegravir as part of their HAART regimen were recruited. HIV-infected 
postmenopausal women were raltegravir naïve at the time of enrollment.
All subjects underwent intensive screening within 28 days prior to enrollment. Screening 
procedures consisted of a complete medical history review, physical examination, and 
comprehensive laboratory studies, including screening for sexually transmitted infections 
such as syphilis, gonorrhea, chlamydia and trichomoniasis. Subjects were excluded for any 
clinically relevant biochemical, physical or pelvic abnormalities, or other clinical condition 
deemed to increase subject risk or to potentially compromise study results. Additionally, 
women were excluded if they had an allergy to any component of the study product, were on 
a concomitant medication that had the potential to change the typical pharmacokinetic 
parameters by ≥30%, or were receiving hormone replacement therapy (ie oral, topical, or 
transdermal estrogen preparations or androgen replacement). Subjects were not eligible if 
they were unwilling or unable to remain abstinent from all sexual activity and insertion of all 
vaginal products starting 72 hours prior to enrollment until study completion, to limit 
alcohol consumption to <14 beverages per week, and to limit acetaminophen use to <1gm/
day. Premenopausal subjects were eligible if they had a fully intact genital tract; 
documentation of a normal Pap smear within the previous year; screened negative for 
sexually transmitted diseases and bacterial vaginosis; and were willing to use at least one of 
the following forms of acceptable contraception for the duration of the study: abstinence, 
bilateral tubal ligation, condoms with spermicide or foam, stable male partner with 
vasectomy, female only partners, or oral hormonal contraception (started at least 3 months 
prior to enrollment).
Cohort-specific enrollment criteria were also defined. HIV-negative premenopausal women 
were required to be 18-49 years of age (inclusive at the date of screening), have regular 
menstrual cycles, and have a body mass index (BMI) of 18-30kg/m2 with total body weight 
greater than 50kg. These women underwent anonymous HIV testing using a standard HIV 
1/2 ELISA (Abbott Laboratories, Abbott Park, IL) with pooled HIV-1 PCR testing to 
confirm that they were HIV-negative. All HIV-infected women were required to have at least 
one positive HIV test or detectable plasma HIV RNA prior to, or during the screening 
process. HIV-infected premenopausal women were eligible if they were 18-49 years of age; 
had been receiving raltegravir 400mg twice daily for at least 3 weeks as part of their 
HAART regimen; and had missed ≤ 6 raltegravir doses in the month prior and no doses in 
the 3 days prior to the pharmacokinetic visit. HIV-infected postmenopausal women were 
eligible if they were 18 years or older and their last menstrual period occurred >12 months 
from the time of screening without another identifiable etiology for amenorrhea. 
Biochemical confirmation of menopause was performed at screening and defined as an 
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estradiol level <20 pg/mL with a follicle stimulating hormone level of > 35 mIU/mL. 
Postmenopausal subjects with hysterectomy and/or oophorectomy at least 6 months prior to 
enrollment were eligible. Lastly, HIV-infected postmenopausal women were eligible if they 
were raltegravir naïve and either initiating as part of their first regimen or changing to a new 
regimen containing raltegravir 400mg twice-daily.
Study Visits
Vital signs, serum chemistries, and complete blood counts were performed at each study 
visit. Pregnancy tests were administered before each visit for all premenopausal women. 
Women were assessed for medication adherence and adverse events with a standardized 
daily questionnaire while on study. HIV-negative premenopausal and HIV-infected 
postmenopausal subjects demonstrating at least 80% compliance to study drug during the 
study period were eligible for the second PK visit. All adverse events were graded using the 
Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events 
[10].
The initial PK evaluation occurred within 5-7 days following the end of premenopausal 
subjects’ menses. Study drug was provided by Merck Sharp & Dohme Corp (Whitehouse, 
NJ, USA) for the HIV-negative volunteers and self-supplied by HIV-infected volunteers. 
After confirming eligibility, subjects were admitted to the Clinical Translational Research 
Center (CTRC) the evening before each intensive pharmacokinetic (PK) evaluation. All 
doses immediately preceding pharmacokinetic sampling were observed by study staff. 
Premenopausal subjects received a standard 500 kcal, 20-25 gm fat meal 30 min before 
dosing, whereas postmenopausal subjects were fasting for a minimum of 8 hours before 
dosing.
Sample Collection and Processing
Nine paired BP and CVF samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, and 
12 hours post dose on Day 1 (first dose) and on Day 7 (steady state) from HIV-negative 
premenopausal women. Eight paired samples were collected at 0.5, 1, 2, 4, 6, 8, 10, and 12 
hours post dose from HIV-infected premenopausal women already dosed to steady state 
conditions at the time of enrollment. Seven paired samples were collected at pre-dose and at 
1, 2, 4, 6, 8, and 12 hours post dose on Day 1 (first dose) and Day 30 (steady state) from 
HIV-infected postmenopausal women.
Whole blood was collected using 3ml K2EDTA tubes (BD Diagnostics, Franklin Lakes, NJ, 
USA) and centrifuged at 1300g at 4°C for 15 minutes. Approximately 1.5ml of BP from 
each sample was aliquoted into labeled cryovials and stored at −80°C until analysis. CVF 
was self-collected via direct aspiration with an aspiration device as previously 
described[11,12], transferred to labeled cryovials, and stored at −80°C until analysis.
Sample Analyses
BP and CVF were analyzed using high performance liquid chromatography with mass 
spectrometry detection (HPLC-MS) methods validated by the UNC Center for AIDS 
Research (CFAR) Clinical Pharmacology and Analytical Chemistry Core [13,14]. The 
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dynamic range for raltegravir in BP was 20-10,000ng/mL and in CVF was 50-10,000ng/mL 
with a minimum of 90% accuracy, and inter-and intra-day variability of 2.4-7.9% and 
1.4-3.8%, respectively [15-17].
Statistical Analysis
The sample size for each cohort of women was pragmatically chosen to generate preliminary 
pharmacokinetic data adequate for understanding penetration of raltegravir into the female 
genital tract. Subject demographic information was collected, summarized descriptively and 
presented as median (range). Pharmacokinetic parameters were estimated using 
noncompartmental methods (Phoenix WinNonlin Pro 6.3; Certara, L.P., St. Louis, MO, 
USA). Maximum concentration (Cmax), time at maximum concentration (Tmax), and 
concentration 12 hours after dosing (C12h) were determined by visual inspection of the 
subject profiles, and the log-linear trapezoidal method was used to calculate the area-under-
the-concentration-time-curve over the 12-hour dosing interval (AUC0-12h). Sample 
concentrations below the limit of quantification were imputed at 50% the lower limit of 
quantification. Sample concentrations below the limit of detection were assigned 0.1ng/ml. 
Descriptive statistics using SigmaPlot 11.0 Software (Systat Software Inc, San Jose, CA, 
USA) were performed. An ANOVA rank sum test with Bonferroni corrections for multiple 
comparisons were conducted for steady state AUC0-12h. Pharmacokinetic data are presented 
as median (interquartile range [IQR]) for BP and CVF. Accumulation ratios were calculated 
utilizing the equation: steady state AUC0-12h ÷ first dose AUC0-12h.
Results
Demographics
A total of 18 women (7 HIV-negative premenopausal; 6 HIV-infected premenopausal; and 5 
HIV-infected postmenopausal) underwent intensive pharmacokinetic sampling. 
Demographic information for the three groups of women is summarized in Table 1. The age 
of HIV-negative premenopausal women, HIV-infected premenopausal women, and HIV-
infected postmenopausal women ranged from 19-46, 29-45, and 45-68 years, respectively. 
While 100% of HIV-negative women were white, the majority of both HIV-infected groups 
were black. HIV-infected premenopausal women had a median BMI that was 24-33% 
higher. The majority of HIV-infected women were on a regimen that included either 
raltegravir with tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC, Truvada®, 
Gilead Sciences, Foster City, CA) or raltegravir with TDF/FTC and a protease inhibitor (PI). 
One HIV-infected participant’s regimen included a PI with maraviroc, a CCR5 antagonist, 
and etravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI). The average time 
on raltegravir for HIV-infected premenopausal women was approximately one year prior to 
pharmacokinetic evaluation. Two of the 5 HIV-infected postmenopausal women were 
HAART-naïve prior to enrollment.
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First dose PK was obtained in HIV-negative premenopausal women and HIV-infected 
postmenopausal women only. The concentration-time profiles in BP and CVF of these two 
groups of women are graphically depicted in Figure 1. Raltegravir demonstrated rapid 
absorption following oral administration. Within 1 hour of dosing, all subjects in both 
groups had detectable concentrations of raltegravir in BP.
In CVF, only 2 of 7 subjects from the HIV-negative group had quantifiable raltegravir 
concentrations by 4 hours post-dose with a median Tmax of 8 hours. Additionally, HIV-
negative women exhibited relatively low exposure [median (IQR) AUC0-12h=1720 
(305-5288) hr*ng/mL]. Raltegravir CVF concentrations were detected as early as 1 hour 
after the first dose for 3 of the 5 HIV-infected postmenopausal women with a median Tmax 
of 12 hours. We observed relatively high exposure [median (IQR) AUC0-12h=13797 
(11066-19563) hr*ng/mL] in the CVF of HIV-infected postmenopausal women. The 
pharmacokinetic estimates and CVF:BP AUC0-12h ratios of raltegravir are shown in Table 2. 
There was a large degree of variability around the point estimates for both groups. The 
median CVF:BP ratio was 0.4 (0.07-2.0) in HIV-negative premenopausal women and 4 
(1.0-5.4) in HIV-infected postmenopausal women.
Steady State Conditions
All three groups of women contributed to steady state pharmacokinetic profiles. The steady 
state BP and CVF concentration time profiles are graphically depicted in Figures 2A and 2B, 
respectively. There were no significant differences in BP AUC0-12h between any of the 
groups (Table 3). The C12h appeared to be highest in the CVF of HIV-infected 
postmenopausal women [958 (313-1252) ng/mL] compared to HIV-negative premenopausal 
women [0.1 (0.1-798) ng/mL] and HIV-infected premenopausal women [447 (181-546) ng/
mL]. The median (IQR) CVF AUC0-12h appeared lower in HIV-negative premenopausal 
women [3164 (1156-9540) ng*hr/mL] compared to the HIV-infected premenopausal women 
[11465 (9725-17138) ng*hr/mL], and HIV-infected postmenopausal women [9568 
(4271-24306) ng*hr/mL]. However, this trend was not statistically different (p=0.08).
At steady state, the HIV-negative women demonstrated a median CVF:BP AUC0-12h ratio of 
0.46 (0.2-1.1). In contrast, HIV-infected premenopausal women and postmenopausal women 
demonstrated median ratios of 3.9 (1.2-6.7) and 1.4 (0.7-4.3), driven primarily by 
differences in CVF pharmacokinetics. With repeated dosing, HIV-negative premenopausal 
women exhibited a 1.5- and 3-fold increase in raltegravir CVF and plasma exposure, 
respectively. CVF and BP exposure was nearly equivalent (1.3-fold and 0.9-fold change with 
repeated dosing) in HIV-infected postmenopausal women.
Discussion
This study characterizes raltegravir exposure in the genital tract of HIV-negative 
premenopausal women and HIV-infected postmenopausal women following a single dose. 
With the first dose of raltegravir, we observed a high degree of penetration into the genital 
Cottrell et al. Page 6













tract of HIV-infected postmenopausal women with a (median CVF:BP AUC=4). In HIV-
negative premenopausal women exhibited only a modest degree of penetration into the 
genital tract with a (median CVF:BP AUC=0.4). Although not statistically significant 
(p=0.08), steady state exposure in the female genital tract appeared to be lowest in HIV-
negative premenopausal women suggesting altered mechanisms of drug distribution. These 
findings are important considerations as antiretrovirals are evaluated for prevention 
strategies such as pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) in 
HIV-negative individuals, as well as treatment as prevention (TasP) in HIV-infected 
individuals.
In the clinical setting, raltegravir exhibits large inter- and intra-individual variability in 
plasma pharmacokinetics, which does not impact systemic virologic outcomes in HIV-
infected individuals receiving 400mg twice daily [18]. Raltegravir is primarily eliminated by 
glucuronidation via uridine-diphosphate glucuronosyltransferase (UGT)1A1 and, to a lesser 
extent, renally excreted [19]. Differences in UGT1A1 polymorphisms and glomerular 
filtration rates may account for the wide inter-individual variability in plasma raltegravir 
exposure observed in this and other studies. Similarly wide variability in raltegravir exposure 
was observed in genital secretions following single or multiple doses (Figures 1 and 2).
Under steady state conditions, CVF exposure between HIV-negative premenopausal women, 
HIV-infected premenopausal women, and HIV-infected postmenopausal women exhibited a 
non-significant trend towards lower exposure in HIV-negative premenopausal women. 
Normalizing the genital tract exposure to BP exposure did not correct this trend, suggesting 
local influences within the vaginal and cervical mucosa. Recently, the expression of drug 
transporters within the vaginal and cervical mucosa has been investigated. Our group[20] 
and others[21] have identified high expression of drug efflux transporters (including p-
glycoprotein) in the female genital tract. P-glycoprotein expression in the female genital 
tract negatively correlates with age and, in one study, was decreased by 17% in 
postmenopausal women compared to premenopausal women [20]. Given that raltegravir is a 
p-glycoprotein substrate[23], our finding that raltegravir exposure in the female genital tract 
is 4 and 1.4-fold higher than the BP after single and repeated doses for postmenopausal 
women is consistent with decreased p-glycoprotein expression and activity.
The expression of p-glycoprotein and other MDR1 transporters is also regulated by 
inflammatory cytokines released during pro-inflammatory states through complex 
modulation pathways [24,25]. For example, the pro-inflammatory cytokines, IL-6 and IL-1β, 
have been shown to modestly attenuate p-glycoprotein and BCRP expression, whereas TNF-
alpha strongly augments p-glycoprotein and attenuates BCRP [26]. Although beyond the 
scope of the current investigation, it is possible that low-grade inflammation in the female 
genital tract of HIV-infected women results in attenuated p-glycoprotein expression and 
subsequently increased raltegravir exposure. In support of this notion, higher raltegravir 
exposure in the CVF compared to the BP has been previously observed in women with 
bacterial vaginosis [27]. In our study, 2 of 5 postmenopausal women were provided a full 
course of treatment for bacterial vaginosis but not rescreened prior to enrollment. 
Additionally, genital HIV RNA positively correlates with IL-6 and IL-1β in the female 
genital tract[28] and has been observed in women on antiretroviral therapy despite 
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undetectable plasma HIV RNA [5]. Thus, the trend towards increased raltegravir exposure in 
HIV-infected women vs negative women may be due to attenuated p-glycoprotein efflux 
transporter expression secondary to inflammation in the genital tract. Finally, the inter-
individual variability of raltegravir exposure in the genital tract may be reflecting the 
differential hormonal and inflammatory states in our participants.
Our previous work has demonstrated marked differences in penetration of antiretrovirals 
both within and between therapeutic drug classes in the female genital tract [11,29]. 
Pertinent to this study, the second-generation INSTI, dolutegravir, has relatively low 
distribution in the female genital tract when compared to BP with a CVF:BP AUC ratio of 
0.07 [30]. In comparison, raltegravir exposure in all three groups of women was 
considerably higher (eg, ≥ 0.4). In the HIV-infected pre- and postmenopausal women, 
raltegravir genital tract exposure is 1.4- to 4-fold higher than BP, respectively. Given this 
relatively high penetration, coupled with the recent reformulation to facilitate once daily 
dosing [31], raltegravir may be well-suited for primary and secondary prevention.
All women undergo alterations in endogenous hormones across the lifespan yet studies 
exploring the effect of hormones on antiretroviral pharmacokinetics have focused on 
pregnancy and contraception [32,33]. Observational data suggests exogenous hormones 
administered for contraception may affect HIV acquisition and transmission[34] 
theoretically due to changes in the female genital tract environment. As the population of 
aging women infected with, or susceptible to, HIV continues to increase[35], quantifying 
antiretroviral pharmacokinetics and pharmacodynamics in older women will become 
increasingly important. Previous studies have not compared genital tract exposure of 
antiretroviral agents in HIV-negative and HIV-infected women or women of different 
menopausal status. These data indicate HIV infection and menopausal status may influence 
local raltegravir disposition and potentially other antiretroviral pharmacokinetics. Taken 
together, these findings illustrate the complexity and unpredictability of antiretroviral 
pharmacokinetics in the female genital tract.
The lack of any statistically significant differences in steady state AUC0-12h may be a 
consequence of the small sample size as suggested by the lower exposure in HIV-negative 
premenopausal women. Despite this limitation, these data provide reasonable estimates of 
central tendency that support the need for larger clinical studies to confirm our findings. The 
lack of first dose pharmacokinetics in HIV-infected premenopausal women does not allow 
for full pharmacokinetic comparisons of the three cohorts. Additionally, the lack of an HIV-
negative postmenopausal cohort makes discerning the effect of HIV infection vs menopausal 
status on raltegravir pharmacokinetics difficult. The differing proportion of black women 
among our cohorts are unlikely to confound the pharmacokinetic data presented herein, 
given that the Raltegravir early therapy in African-Americans living with HIV (REAL) study 
did not identify any raltegravir plasma pharmacokinetic differences based on race[15]. 
Finally, in our study premenopausal women received raltegravir in the fed state while 
postmenopausal women were in the fasted state. Administration of a moderate fat meal 
results in clinically insignificant changes in raltegravir AUC, Cmax, and C12h, which are 
increased by 13%, 5%, and 66%, respectively[19]. Given that our fasted postmenopausal 
group tended to exhibit higher raltegravir PK parameters, it is unlikely that the 
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pharmacokinetic findings reported herein can be attributed to these methodological 
differences.
In summary, these data indicate that HIV and menopausal status may be important 
influencers of the distribution of antiretrovirals into the female genital tract. HIV-negative 
premenopausal women had the lowest relative penetration (0.46) of raltegravir into the CVF 
of all three groups of women in our study. In comparison, raltegravir exposure in the genital 
tract of HIV-infected women was 3.9-fold and 1.4-fold higher than BP for pre and 
postmenopausal women, respectively. Given that genital tract penetration was enhanced in 
both groups of HIV-infected women, raltegravir may be a favorable option when choosing 
an INSTI-containing regimen for women such as those in an HIV serodiscordant 
relationship. While the concentrations of raltegravir necessary to suppress HIV in the female 
genital tract have yet to be determined, our findings indicate raltegravir effectively penetrates 
the site most commonly associated with HIV acquisition and transmission in women 
worldwide. The prospect of a once daily formulation may support raltegravir as a preferred 
INSTI for various prevention strategies such as TasP, PrEP and PEP.
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Median (IQR) raltegravir concentrations over time in the blood plasma (BP) and 
cervicovaginal fluid (CVF) following a single dose of raltegravir in HIV-uninfected women 
and HIV-infected postmenopausal women
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Median (IQR) raltegravir concentrations over time in the (A) blood plasma (BP) and (B) 
cervicovaginal fluid (CVF) at steady state in HIV-uninfected women, HIV-infected 
premenopausal women and HIV-infected postmenopausal women.
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Age, years 21 (19-46) 42 (33-45) 54 (45-68)
Race/Ethnicity
b
 Black 0 (0) 5 (83) 3 (60)
 White 7 (100) 1 (17) 2 (40)
Weight, kg 65 (52-73) 98 (73-115) 71 (62-83)
BMI, kg/m2 23.5 (20.8-27.1) 35.4 (27.4-44.2) 26.8 (23.9-28.5)
Other ART
c
 TDF/FTC N/A 2 (33) 2 (40)
 TDF/FTC + PI N/A 4 (67) 1 (2)
 NNRTI + PI + MVC N/A 0 (0) 1 (2)
 PI N/A 0 (0) 1 (2)
HIV diagnosis, years N/A 15 (2-18) 13.4 (4-20)







Antiretrovirals (in addition to raltegravir): PI=darunavir/ritonavir, lopinavir/ritonavir, and atazanavir/ritonavir; NNRTI=etravirine













Cottrell et al. Page 15
Table 2




















































75% of first dose CVF samples collected post dose were BLD, and all samples collected over the dosing interval for two subjects were BLD. BLD 
PK parameters were imputed as 0.1 ng/ml for statistical analysis.
c
Excludes PK estimates for two subjects who exhibited undetectable CVF samples for entire dosing interval BP=blood plasma; 
CVF=cervicovaginal fluid; IQR=interquartile range; PreMW=premenopausal women; PostMW=postmenopausal women
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Table 3













































































27% of CVF samples collected were BLD. BLD PK parameters were imputed as 0.1 ng/ml for statistical analysis. BP=blood plasma; 
CVF=cervicovaginal fluid; IQR=interquartile range; PreMW=premenopausal women; PostMW=postmenopausal women
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